Abstract |
This randomized, double-blind, placebo-controlled exploratory study examined the efficacy and safety of a low-dose oral contraceptive ( Mircette), desogestrel/ ethinyl estradiol [DSG/EE] and ethinyl estradiol [EE]) in relieving the symptoms of dysmenorrhea. Twenty-three clinics in the United States enrolled 77 women (age < or =32 years) with primary dysmenorrhea documented for at least four consecutive cycles. Forty participants received DSG/EE&EE and 37 received placebo for four consecutive 28-day cycles. The intensity of menstrual-related distress was measured with the Menstrual Distress Questionnaire (MDQ). Patient diaries were used to assess number of school/work days missed as well as the use of rescue medication. Participants receiving DSG/EE&EE recorded reduced menstrual pain severity, lower total MDQ scores, and significantly less menstrual cramping. No significant change in bloating, anxiety, loneliness, weight gain, or acne was reported. The DSG/EE&EE formulation shows promise for the treatment of primary dysmenorrhea and was well tolerated by the participants in this study.
|
Authors | Susan L Hendrix, Nancy J Alexander |
Journal | Contraception
(Contraception)
Vol. 66
Issue 6
Pg. 393-9
(Dec 2002)
ISSN: 0010-7824 [Print] United States |
PMID | 12499030
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2002 Elsevier Science Inc. |
Chemical References |
- Contraceptives, Oral, Synthetic
- Placebos
- Ethinyl Estradiol
- Desogestrel
|
Topics |
- Adult
- Contraceptives, Oral, Synthetic
(administration & dosage, adverse effects)
- Desogestrel
(administration & dosage, adverse effects)
- Double-Blind Method
- Dysmenorrhea
(drug therapy)
- Ethinyl Estradiol
(administration & dosage)
- Female
- Headache
(chemically induced)
- Humans
- Placebos
- Treatment Outcome
- United States
|